|
 |
Cellectis SA
28,
rue du Docteur Roux
75724, Paris Cedex 15
FranceE-mail:
mail@cellectis.com
Tel : +33 1 40 61 34 18
Fax : +33 1 45 68 84 53
Website: www.cellectis.com |
|
Cellectis S.A. was founded in
1999, as a spin-off from the Pasteur
Institute. Today, Cellectis is the world
leader in applying the technology of
Meganuclease Recombination
Systems to in vivo genome engineering and Genome Surgery.
The
company is focused on the research and development of custom-made
Meganucleases
for in vivo DNA interventions
and also provides new tools for rational reverse genetics and
targeted recombination. Cellectis develops Meganucleases that can induce
unique sitedirected double-strand breaks in a living cell, and can be
used for biotechnological and therapeutical applications. Cellectis is
focusing on bringing "Genome Surgery" to clinic as a genuine new
approach in molecular medicine and its mission is to turn Meganuclease
Recombination Systems into therapeutic drugs for gene repair. This
approach aims at repairing genomic DNA sequences causing diseases such
as mutated genes or resident viruses. Cellectis first key market for
human genome surgery is the possible cure of severe inborn diseases. |
|
|